Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238

Naoual Benali, Pierre Cordelier, Denis Calise, Philippe Pagès, Philippe Rochaix, Attila Nagy, Jean Pierre Estève, Parviz M. Pour, Andrew V Schally, Nicole Vaysse, Christiane Susini, Louis Buscail

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

The sst2 somatostatin receptor mediates the antiproliferative effects of somatostatin analogs. The present study demonstrates that stable expression of sst2 in the hamster pancreatic cancer cells PC-1 and PC-1.0 activates an autocrine negative loop leading to an in vitro inhibition of cell proliferation. In vivo studies conducted in Syrian golden hamsters after orthotopic implantation of PC-1.0 cells showed that both tumor growth and metastatic progression of allografts containing 100% of sst2-expressing cells were significantly inhibited for up to 20 days after implantation, as compared with control allografts that did not express sst2. A local antitumor bystander effect was observed after induction of mixed tumors containing a 1:3 ratio of sst2-expressing cells to control cells. Tumor volume and incidence of metastases of mixed tumors were significantly reduced at day 13 post implantation. This effect decreased with time as at day 20, growth of mixed tumors was similar to that of control tumors. After administration of the cytotoxic somatostatin conjugate AN-238 on day 13, antitumor bystander effect observed in mixed tumors was significantly extended to day 20. We also observed that in vitro invasiveness of sst2-expressing PC-1.0 cells was significantly reduced. Tyrosine dephosphorylation of E-cadherin may participate in restoring the E-cadherin function, reducing in turn pancreatic cancer cell motility and invasiveness. This dephosphorylation depends on the tyrosine phosphatase src homology 2-containing tyrosine phosphatase 1 (SHP-1) positively coupled to sst2 receptor. The inhibitory effect of sst2 gene expression on pancreatic cancer growth and invasion combined with chemotherapy with targeted cytotoxic somatostatin analog administration provides a rationale for a therapeutic approach to gene therapy based on in vivo sst2 gene transfer.

Original languageEnglish
Pages (from-to)9180-9185
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume97
Issue number16
StatePublished - Aug 1 2000
Externally publishedYes

Fingerprint

Somatostatin
Cricetinae
Gene Expression
Growth
Pancreatic Neoplasms
Bystander Effect
Neoplasms
Cadherins
Allografts
Tyrosine
Non-Receptor Type 6 Protein Tyrosine Phosphatase
AN 238
somatostatin receptor 2
Pancreatic Carcinoma
Somatostatin Receptors
Mesocricetus
Tumor Burden
Phosphoric Monoester Hydrolases
Genetic Therapy
Cell Movement

Keywords

  • Bystander effect
  • E-cadherin
  • Experimental gene therapy
  • Targeted chemotherapeutic agent
  • Tumor invasion

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. / Benali, Naoual; Cordelier, Pierre; Calise, Denis; Pagès, Philippe; Rochaix, Philippe; Nagy, Attila; Estève, Jean Pierre; Pour, Parviz M.; Schally, Andrew V; Vaysse, Nicole; Susini, Christiane; Buscail, Louis.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, No. 16, 01.08.2000, p. 9180-9185.

Research output: Contribution to journalArticle

Benali, Naoual ; Cordelier, Pierre ; Calise, Denis ; Pagès, Philippe ; Rochaix, Philippe ; Nagy, Attila ; Estève, Jean Pierre ; Pour, Parviz M. ; Schally, Andrew V ; Vaysse, Nicole ; Susini, Christiane ; Buscail, Louis. / Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. In: Proceedings of the National Academy of Sciences of the United States of America. 2000 ; Vol. 97, No. 16. pp. 9180-9185.
@article{5d24108b33f54d8e863a146b41678651,
title = "Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238",
abstract = "The sst2 somatostatin receptor mediates the antiproliferative effects of somatostatin analogs. The present study demonstrates that stable expression of sst2 in the hamster pancreatic cancer cells PC-1 and PC-1.0 activates an autocrine negative loop leading to an in vitro inhibition of cell proliferation. In vivo studies conducted in Syrian golden hamsters after orthotopic implantation of PC-1.0 cells showed that both tumor growth and metastatic progression of allografts containing 100{\%} of sst2-expressing cells were significantly inhibited for up to 20 days after implantation, as compared with control allografts that did not express sst2. A local antitumor bystander effect was observed after induction of mixed tumors containing a 1:3 ratio of sst2-expressing cells to control cells. Tumor volume and incidence of metastases of mixed tumors were significantly reduced at day 13 post implantation. This effect decreased with time as at day 20, growth of mixed tumors was similar to that of control tumors. After administration of the cytotoxic somatostatin conjugate AN-238 on day 13, antitumor bystander effect observed in mixed tumors was significantly extended to day 20. We also observed that in vitro invasiveness of sst2-expressing PC-1.0 cells was significantly reduced. Tyrosine dephosphorylation of E-cadherin may participate in restoring the E-cadherin function, reducing in turn pancreatic cancer cell motility and invasiveness. This dephosphorylation depends on the tyrosine phosphatase src homology 2-containing tyrosine phosphatase 1 (SHP-1) positively coupled to sst2 receptor. The inhibitory effect of sst2 gene expression on pancreatic cancer growth and invasion combined with chemotherapy with targeted cytotoxic somatostatin analog administration provides a rationale for a therapeutic approach to gene therapy based on in vivo sst2 gene transfer.",
keywords = "Bystander effect, E-cadherin, Experimental gene therapy, Targeted chemotherapeutic agent, Tumor invasion",
author = "Naoual Benali and Pierre Cordelier and Denis Calise and Philippe Pag{\`e}s and Philippe Rochaix and Attila Nagy and Est{\`e}ve, {Jean Pierre} and Pour, {Parviz M.} and Schally, {Andrew V} and Nicole Vaysse and Christiane Susini and Louis Buscail",
year = "2000",
month = "8",
day = "1",
language = "English",
volume = "97",
pages = "9180--9185",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "16",

}

TY - JOUR

T1 - Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238

AU - Benali, Naoual

AU - Cordelier, Pierre

AU - Calise, Denis

AU - Pagès, Philippe

AU - Rochaix, Philippe

AU - Nagy, Attila

AU - Estève, Jean Pierre

AU - Pour, Parviz M.

AU - Schally, Andrew V

AU - Vaysse, Nicole

AU - Susini, Christiane

AU - Buscail, Louis

PY - 2000/8/1

Y1 - 2000/8/1

N2 - The sst2 somatostatin receptor mediates the antiproliferative effects of somatostatin analogs. The present study demonstrates that stable expression of sst2 in the hamster pancreatic cancer cells PC-1 and PC-1.0 activates an autocrine negative loop leading to an in vitro inhibition of cell proliferation. In vivo studies conducted in Syrian golden hamsters after orthotopic implantation of PC-1.0 cells showed that both tumor growth and metastatic progression of allografts containing 100% of sst2-expressing cells were significantly inhibited for up to 20 days after implantation, as compared with control allografts that did not express sst2. A local antitumor bystander effect was observed after induction of mixed tumors containing a 1:3 ratio of sst2-expressing cells to control cells. Tumor volume and incidence of metastases of mixed tumors were significantly reduced at day 13 post implantation. This effect decreased with time as at day 20, growth of mixed tumors was similar to that of control tumors. After administration of the cytotoxic somatostatin conjugate AN-238 on day 13, antitumor bystander effect observed in mixed tumors was significantly extended to day 20. We also observed that in vitro invasiveness of sst2-expressing PC-1.0 cells was significantly reduced. Tyrosine dephosphorylation of E-cadherin may participate in restoring the E-cadherin function, reducing in turn pancreatic cancer cell motility and invasiveness. This dephosphorylation depends on the tyrosine phosphatase src homology 2-containing tyrosine phosphatase 1 (SHP-1) positively coupled to sst2 receptor. The inhibitory effect of sst2 gene expression on pancreatic cancer growth and invasion combined with chemotherapy with targeted cytotoxic somatostatin analog administration provides a rationale for a therapeutic approach to gene therapy based on in vivo sst2 gene transfer.

AB - The sst2 somatostatin receptor mediates the antiproliferative effects of somatostatin analogs. The present study demonstrates that stable expression of sst2 in the hamster pancreatic cancer cells PC-1 and PC-1.0 activates an autocrine negative loop leading to an in vitro inhibition of cell proliferation. In vivo studies conducted in Syrian golden hamsters after orthotopic implantation of PC-1.0 cells showed that both tumor growth and metastatic progression of allografts containing 100% of sst2-expressing cells were significantly inhibited for up to 20 days after implantation, as compared with control allografts that did not express sst2. A local antitumor bystander effect was observed after induction of mixed tumors containing a 1:3 ratio of sst2-expressing cells to control cells. Tumor volume and incidence of metastases of mixed tumors were significantly reduced at day 13 post implantation. This effect decreased with time as at day 20, growth of mixed tumors was similar to that of control tumors. After administration of the cytotoxic somatostatin conjugate AN-238 on day 13, antitumor bystander effect observed in mixed tumors was significantly extended to day 20. We also observed that in vitro invasiveness of sst2-expressing PC-1.0 cells was significantly reduced. Tyrosine dephosphorylation of E-cadherin may participate in restoring the E-cadherin function, reducing in turn pancreatic cancer cell motility and invasiveness. This dephosphorylation depends on the tyrosine phosphatase src homology 2-containing tyrosine phosphatase 1 (SHP-1) positively coupled to sst2 receptor. The inhibitory effect of sst2 gene expression on pancreatic cancer growth and invasion combined with chemotherapy with targeted cytotoxic somatostatin analog administration provides a rationale for a therapeutic approach to gene therapy based on in vivo sst2 gene transfer.

KW - Bystander effect

KW - E-cadherin

KW - Experimental gene therapy

KW - Targeted chemotherapeutic agent

KW - Tumor invasion

UR - http://www.scopus.com/inward/record.url?scp=0034254910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034254910&partnerID=8YFLogxK

M3 - Article

VL - 97

SP - 9180

EP - 9185

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 16

ER -